Two Manic Episodes Related to a Levetiracetam-Based Treatment in a 34-Year-Old Female Patient

Meyrel, Manon; Veyrier, Marc; Nieto, I.; Bellivier, Frank; Geoffroy, Pierre A.

doi:10.1097/jcp.0000000000000978

Cited by 6 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Studies suggest that LEV, an antiepileptic with known neuropsychiatric side effects, may have short duration antimanic effects in adults and elderly patients diagnosed with bipolar disorder. 5,15 To the best of our knowledge, there are three reported cases of LEV-induced mania, 9,10,16 and one of LEV-induced mania-like symptoms, 17 in the literature. Although not published, the European ADR Database has 32 case reports of mania following LEV treatment.…”

Section: Discussionmentioning

confidence: 97%

Levetiracetam induced hypomania: a case report

Altınöz

Biltekin

et al. 2019

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Levetiracetam (LEV) is a newer second-generation antiepileptic drug that is found to be effective in tonic-clonic seizures, partial onset seizures, and myoclonic seizures. Among antiepileptic drugs, LEV is usually known for fewer adverse drug reactions. Psychiatric disorders after the administration of LEV have been reported in the literature. There are many case reports on LEV-induced psychosis, but there are only three case reports of mania induced by LEV use. In this report, we present a case with no history of psychiatric disorder who had a hypomania episode after receiving LEV for epilepsy treatment. The development of manic symptoms with LEV therapy is unusual. Clinicians should consider monitoring patients closely for treatment-related psychological symptoms and psychotic symptoms, including the possibility of mania.

show abstract

Section: Discussionmentioning

confidence: 97%

Levetiracetam induced hypomania: a case report

Altınöz

Biltekin

et al. 2019

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

show abstract

“…However, in this study, bipolar disorder patients were examined in their depressive phase – not mania (Saricicek et al , 2011). There are also some case reports in which levetiracetam was considered to have a relationship with emerging manic symptoms (Park et al , 2014; Altinöz et al , 2019; Ekinci et al , 2019; Meyrel et al , 2019).…”

Section: Discussionmentioning

confidence: 99%

Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability

Zarezadeh

Arbabi

Shamabadi

et al. 2021

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Unsatisfactory responses to bipolar disorder treatments have necessitated novel therapeutic approaches. Evidence of levetiracetam's effectiveness in mania was reported in previous studies. This study evaluated its efficacy, safety and tolerability as an adjunct to quetiapine in mania. Forty-four patients with Young Mania Rating Scale (YMRS) score ≥20 entered and were randomized to receive levetiracetam plus quetiapine or placebo plus quetiapine for 6 weeks. Patients were assessed using the YMRS and Beck Scale for Suicidal Ideations (BSSI) at baseline and weeks 2, 4 and 6. Changes in the scores, remission rates and response to treatment were compared between the groups. Forty patients completed the trial. The general linear model (GLM) repeated measures demonstrated a significant effect for time × treatment interaction on the YMRS score during the trial (P = 0.04). A greater reduction in YMRS scores was seen in the levetiracetam group compared with the placebo group from baseline to week 4 (P = 0.045). Response to treatment was significantly better in the levetiracetam group (P = 0.046). No significant effect for time × treatment interaction on BSSI score was seen in GLM repeated measures. Finally, there was no significant difference in the frequency of adverse events. Adjunctive levetiracetam is effective, safe and well-tolerated in patients with mania. Further high-quality, large-scale trials are recommended.

show abstract

“…The results of several studies in children and adults, as well as a review study, showed that drowsiness is one of the most common and perhaps the most common psychiatric side effects of Levetiracetam ( well as a review study, showed that drowsiness is one of the most common and perhaps the most common psychiatric side effects of Levetiracetam (30)(31)(32)(33)(34)(35)(36). Several rare case studies have reported a rare, but essential complication of mania due to Levetiracetam in children and adults (37)(38)(39).…”

Section: Drowsinessmentioning

confidence: 99%

Levetiracetam "Narrative Review of Neuropsychiatric Issues"

Bidaki¹,

Afshang²

2022

APTJ

View full text Add to dashboard Cite

Introduction Levetiracetam, an anti-epileptic drug, is usually used as an adjunctive treatment of partial-onset seizures with or without secondary generalization. In this article, various neuropsychiatric effects of Levetiracetam are investigated. Methods The following databases were searched: PUBMED, Google Scholar, MEDLINE, Embase, ProQuest, and Science Direct. The articles searched in the mentioned databases were from 2003 to 2021. Ninety-nine articles were selected, fifteen articles such as case reports and letters to the editor were removed due to low scientific credibility, and eighty-four articles were selected. Due to the small number of articles, articles in the form of case reports and letters to the editor were also used to write about mania. Results Case reports showed that some cases of behavioral disorders, aggression, and depression had been observed following the use of Levetiracetam. In this study, various evidence were collected to determine the performance of Levetiracetam and to what extent it can have important and vital side effects. This drug can strengthen suicidal thoughts and aggression in consuming patients, especially the patients with other underlying diseases. Conclusion According to the side effects mentioned for Levetiracetam, it is suggested that psychiatrists and neurologists pay more attention to these side effects when prescribing.

show abstract

Two Manic Episodes Related to a Levetiracetam-Based Treatment in a 34-Year-Old Female Patient

Cited by 6 publications

References 3 publications

Levetiracetam induced hypomania: a case report

Levetiracetam induced hypomania: a case report

Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability

Levetiracetam "Narrative Review of Neuropsychiatric Issues"

Contact Info

Product

Resources

About